- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1005342-46-0] LCL161
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-15518 |
| Brand: | MCE |
| CAS: | 1005342-46-0 |
Overview
| MDL | MFCD23160049 |
|---|---|
| Molecular Weight | 500.63 |
| Molecular Formula | C26H33FN4O3S |
| SMILES | C[C@H](NC)C(N[C@@H](C1CCCCC1)C(N2[C@H](C3=NC(C(C4=CC=C(F)C=C4)=O)=CS3)CCC2)=O)=O |
22 Publications Citing Use of MCE
- [1]Immunity. 2021 Aug 10;54(8):1758-1771.e7.
- [2]Adv Mater. 2022 Nov 25;e2208782.
- [3]Cell Death Differ. 2021 Dec 1.
- [4]Cell Death Differ. 2020 May;27(5):1569-1587.
- [5]Dev Cell. 2022 Jan 3;S1534-5807(21)01035-2.
- [6]Cell Death Dis. 2021 Jun 23;12(7):641.
- [7]Cell Death Dis. 2020 Feb 5;11(2):94.
- [8]J Med Chem. 2021 Oct 27.
- [9]J Med Chem. 2019 Oct 24;62(20):9188-9200.
- [10]J Med Chem. 2019 Jun 13;62(11):5616-5627.
- [11]J Med Chem. 2018 Jul 26;61(14):6350-6363.
- [12]Pharmacol Res. 2020 Jul;157:104800.
- [13]Am J Cancer Res. 2020 Sep 1;10(9):2813-2831.
- [14]PLoS One. 2021 Mar 26;16(3):e0248175.
- [15]Exp Mol Pathol. 7 January 2022, 104739.
- [16]Anticancer Agents Med Chem. 2020;20(6):687-699.
- [17]World J Clin Cases. 2021 Jul 6;9(19):5019-5027.
- [18]Pharmazie. 2019 Jun 1;74(6):363-368.
- [19]University of Portland. Department of Biology
- [20]für das Fach der Zahn-, Mund- und Kieferheilkunde an der Medizinischen Fakultät der Julius-Maximilians. 2020 Sep.
- [21]Department of Medical Biology. 2020 Sep.
- [22]bioRxiv. May 2, 2018.
Summary
IC50 & Target
IC50: 35 nM (XIAP, in HEK293 cell), 0.40 nM (cIAP1, in MDA-MB-231) [1]
In Vitro
LCL161 shows anti-proliferative effects and reduces cell viability significantly in Hep3B (IC 50 =10.23 μM) and PLC5 (IC 50 =19.19 μM) cells in a dose-dependent manner. LCL161 induces apoptosis significantly in both the sensitive cell lines in a dose-dependent manner. LCL161 significantly down regulates the expression of cIAP1, starting at very low concentrations. LCL161 at low concentrations inhibits cIAP1 starting at the concentration of 0.5 nM [2] . LCL161 is a small molecule oral IAP antagonist in development for use in combination with cytotoxic agents. The effect of LCL161 on CYP3A4/5 (CYP3A) activity is investigated in vitro. Results in human liver microsomes indicated LCL161 inhibited CYP3A in a concentration- and time-dependent manner (K I of 0.797 µM and K inact of 0.0803 min -1 ). LCL161 activates human PXR in a reporter gene assay and induced CYP3A4 mRNA up to ~5-fold in human hepatocytes [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Tumor-bearing mice are treated with vehicle or LCL161 p.o. at a dose of 50 mg/kg/day, or SC-2001 p.o. at a dose of 10 mg/kg/day, 5 days a week, or in combination for the duration of the study. Tumor growth is significantly inhibited by co-treatment with SC2001 and LCL161 and tumor size in the co-treatment group is only one third of that of the control group at the end of the study [2] . LCL161 is a first-in-class oral Smac mimetic shown to induce degradation of cIAP1 and cleavage of caspase 3 in mouse xenograft models [4] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01098838 | Novartis Pharmaceuticals|Novartis |
Advanced Solid Tumors
|
November 2008 | Phase 1 |
| NCT01934634 | US Oncology Research|Novartis Pharmaceuticals|Delta Clinical Research, LLC |
Metastatic Pancreatic Cancer
|
March 2014 | Phase 1 |
| NCT02649673 | SCRI Development Innovations, LLC|Novartis Pharmaceuticals |
Small Cell Lung Cancer|Ovarian Cancer
|
March 23, 2016 | Phase 1 |
| NCT01240655 | Novartis Pharmaceuticals|Novartis |
Solid Tumors
|
April 2011 | Phase 1 |
| NCT01617668 | Novartis Pharmaceuticals|Novartis |
Breast Cancer
|
August 2012 | Phase 2 |
| NCT03111992 | Novartis Pharmaceuticals|Novartis |
Multiple Myeloma
|
December 18, 2017 | Phase 1 |
| NCT02098161 | M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Novartis Pharmaceuticals |
Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase|Primary Myelofibrosis|Secondary Myelofibrosis
|
December 18, 2014 | Phase 2 |
| NCT02890069 | Novartis Pharmaceuticals|Novartis |
Colorectal Cancer, Non-small Cell Lung Carcinoma (Adenocarcinoma), Triple Negative Breast Cancer, Renal Cell Carcinoma
|
October 14, 2016 | Phase 1 |
| NCT01968915 | Novartis Pharmaceuticals|Novartis |
Neoplasms
|
November 2013 | Phase 1 |
| NCT01955434 | Mayo Clinic|National Cancer Institute (NCI) |
Recurrent Plasma Cell Myeloma|Refractory Plasma Cell Myeloma
|
November 2013 | Phase 2 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 199.75 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.9975 mL | 9.9874 mL | 19.9748 mL |
| 5 mM | 0.3995 mL | 1.9975 mL | 3.9950 mL |
| 10 mM | 0.1997 mL | 0.9987 mL | 1.9975 mL |
References
- [1] Maria Ahn, et al. Potent, Dual cIAP1/XIAP Antagonists Induce Apoptosis in a Melanoma Stem Cell Population.
- [2] Chen KF, et al. Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells. Biochem Pharmacol. 2012 Aug 1;84(3):268-77.
- [3] Dhuria S, et al. Time-dependent inhibition and induction of human cytochrome P4503A4/5 by an oral IAP antagonist, LCL161, in vitro and in vivo in healthy subjects. J Clin Pharmacol. 2013 Jun;53(6):642-53.
- [4] Infante JR, et al. Phase I dose-escalation study of LCL161, an oral inhibitor of apoptosis proteins inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2014 Oct 1;32(28):3103-10.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.